Every earnings call for NGLFINE — management tone, guidance, KPIs and promise tracking, quarter by quarter.
NGLFINE · 3 transcripts · Healthcare · latest Q4 FY26NGL Fine-Chem Limited has 3 earnings calls on record here, a Healthcare company, most recently Q4 FY26. Each quarter is scored on revenue, margins, guidance delivery and the questions management left unanswered — so the gap between what was promised and what was delivered is easy to read.
Revenue (Q4 FY26) ₹149 cr (+57% YoY); EBITDA (Q4 FY26) ₹21 cr (+239% YoY); EBITDA Margin (Q4 FY26) 14.35%. Revenue grew 57% YoY in Q4 FY26 to ₹149.23 crores.
Read full transcript & analysisRevenue (Q2 FY26) ₹120 cr (+29% YoY); EBITDA (Q2 FY26) ₹17 cr (+48% YoY); EBITDA Margin (Q2 FY26) 14.27%. Q2 FY26 Revenue from operations grew 28.64% YoY to INR120.26 crores.
Read full transcript & analysisRevenue (Q4 FY25) ₹95 cr (−5% YoY); EBITDA (Q4 FY25) ₹6 cr (−60% YoY); EBITDA Margin (Q4 FY25) 6.7% (−9% YoY). FY25 Revenue from operations grew 8.7% to INR368.26 crores.
Read full transcript & analysis